Zurich Bio-tech Pharma Ltd Financial Statement

As of May 14, 2025, Zurich Bio-tech Pharma Ltd has a market capitalization of - Cr. Value Research classifies it as a Mega-Cap company.

Yes, Zurich Bio-tech Pharma Ltd is not with a debt-to-equity ratio of .

In FY 2024 , Zurich Bio-tech Pharma Ltd recorded a total revenue of approximately - Cr marking a significant milestone in the company's financial performance.

Zurich Bio-tech Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising annually..

Zurich Bio-tech Pharma Ltd's current PE ratio is .

Zurich Bio-tech Pharma Ltd's ROCE averaged NaN% from the FY ending March NaN to NaN, with a median of NaN%. It peaked at -Infinity% in March NaN, reflecting strong capital efficiency over the period..

Zurich Bio-tech Pharma Ltd's latest EBIT is Rs. - Cr, surpassing the average EBIT of Rs. - Cr over the 5 years..